World Journal of Urology

, Volume 28, Issue 3, pp 253–261 | Cite as

Imaging of advanced renal cell carcinoma

  • Ullrich G. Mueller-Lisse
  • Ulrike L. Mueller-Lisse
Topic Paper



To describe current radiological cross-sectional imaging in the detection and staging of advanced renal cell carcinoma (RCC), defined here as RCC reaching beyond the renal capsule, whether by immediate extension or by metastasis.


Review and summary of current radiological and urological literature, including original articles and reviews, retrieved from the medical data base “PubMed”.


Multi-detector-row computed tomography (MDCT) shows a sensitivity of up to 100% and specificity of about 90% for retroperitoneal disease, venous tumour thrombus, and metastasis, but limited accuracy for lymphadenopathy in RCC. Magnetic resonance imaging (MRI) is applied as a problem-solving modality, with particular strength in imaging metastasis to brain and bone. However, dynamic, contrast-enhanced- (DCE-) and arterial-spin-labelling (ASL-) MRI may help to monitor early response to angiogenesis inhibitor drugs. Ultrasonography (US) shows limited capability of identifying retroperitoneal disease, venous tumour thrombus extension, and metastasis. Positron Emission Tomography with 18-fluoro-desoxy-glucose (FDG-PET) demonstrates modest accuracy for metastasis of RCC, with positive studies being suspicious, while negative studies cannot reliably exclude disease.


MDCT represents the diagnostic mainstay for the detection and staging of RCC. In the wake of new systemic therapies for advanced RCC, including angiogenesis inhibitor drugs, monitoring treatment response may become a new task for cross-sectional imaging.


Renal cell carcinoma Advanced renal cell carcinoma Metastatic renal cell carcinoma Cross-sectional imaging Computed tomography Magnetic resonance imaging Ultrasonography Positron emission tomography Angiogenesis inhibitor drugs Tyrosine-kinase inhibitor drugs 


Conflict of interest statement

There is no conflict of interest.


  1. 1.
  2. 2.
    Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, Scherr M, Reiser MF (2007) Staging of renal cell carcinoma. Eur Radiol 17:2268–2277CrossRefPubMedGoogle Scholar
  3. 3.
    Downs TM, Schultzel M, Shi H, Sanders C, Tahir Z, Sadler GR (2009) Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients. Crit Rev Oncol Hematol 70:59–70CrossRefPubMedGoogle Scholar
  4. 4.
    Atzpodien J et al (2003) Aktuelle Therapiestrategien beim Nierenzellkarzinom. Uni-Med Science. Bremen, LondonGoogle Scholar
  5. 5.
    Oberneder R, Wagner H, Siebels M, Stieber P, Busch M, Weiss M (2003) Nierenzellkarzinom. In: Liedl B (ed) Urogenitale tumoren. Manual tumorzentrum München, 3rd edn. W. Zuckschwerdt, München, pp 79–97Google Scholar
  6. 6.
    Ohlmann CH (2009) [Prognostic factors for survival of patients with metastatic renal cell carcinoma]. Urologe A 48:625–627. (Review in German)Google Scholar
  7. 7.
    Rini BI (2005) New approaches in advanced renal cell carcinoma. Urol Oncol 23(1):65–66PubMedGoogle Scholar
  8. 8.
    Rouviere O, Brunereau L, Lyonnet D, Rouleau P (2002) Staging and follow up of renal cell carcinoma. J Radiol 83:805–822 (discussion 823–824)PubMedGoogle Scholar
  9. 9.
    Sengupta S, Zincke H (2005) Lessons learned in the surgical management of renal cell carcinoma. Urology 66(5 Suppl):36–42CrossRefPubMedGoogle Scholar
  10. 10.
    Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard JJ, Sinescu IC (2009) Guidelines on renal cell carcinoma. Update March 2009. EAU European Association of Urology 2009, p 28Google Scholar
  11. 11.
    Coppenrath EM, Mueller-Lisse UG (2006) Multidetector CT of the kidney. Eur Radiol 16:2603–2611CrossRefPubMedGoogle Scholar
  12. 12.
    Bolton DM, Wong P, Lawrentschuk N (2007) Renal cell carcinoma: imaging and therapy. Curr Opin Urol 17:337–340CrossRefPubMedGoogle Scholar
  13. 13.
    de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM (2008) Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 14:5548–5554CrossRefPubMedGoogle Scholar
  14. 14.
    Schreyer HH, Uggowitzer MM, Ruppert-Kohlmayr A (2002) Helical CT of the urinary organs. Eur Radiol 12:575–591PubMedGoogle Scholar
  15. 15.
    Graser A, Zech CJ, Stief CG, Reiser MF, Staehler M (2009) Bildgebung des Nierenzellkarzinoms. Urologe 48:427–438CrossRefPubMedGoogle Scholar
  16. 16.
    Foley WD (2003) Renal MDCT. Eur J Radiol 45:73–78CrossRefGoogle Scholar
  17. 17.
    Mueller-Lisse UG, Mueller-Lisse UL (2004) Multi-detector CT of the kidneys. In: Multislice CT (ed) Medical radiology—diagnostic imaging. 2nd revised edn. Springer, Berlin, pp 211–232Google Scholar
  18. 18.
    Griffin N, Gore ME, Sohaib SA (2007) Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol 189:360–370CrossRefPubMedGoogle Scholar
  19. 19.
    Tzedakis A, Damilakis J, Perisinakis K, Statakis J, Gourtsoyiannis N (2005) The effect of z overscanning on patient effective dose from multidetector helical computed tomography examinations. Med Physic 32:1621–1629CrossRefGoogle Scholar
  20. 20.
    Ramdave S, Thomas GW, Berlangieri S et al (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166:825–830CrossRefPubMedGoogle Scholar
  21. 21.
    Kang DE, White RL Jr, Zuger JH et al (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806–1809CrossRefPubMedGoogle Scholar
  22. 22.
    Aide N, Cappele O, Bottet P et al (2003) Efficiency of [18F]FDG-PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236–1245CrossRefPubMedGoogle Scholar
  23. 23.
    Majhail NS, Urbain JL, Albani JM et al (2003) F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21:3995–4000CrossRefPubMedGoogle Scholar
  24. 24.
    Jadvar H, Kherbache HM, Pinski JK, Conti PS (2003) Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 60:395–400PubMedGoogle Scholar
  25. 25.
    Safaei A, Figlin R, Hoh CK et al (2002) The usefulness of F-18 deoxyglucose wholebody positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 57:56–62PubMedGoogle Scholar
  26. 26.
    Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U (2009) Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519–524CrossRefPubMedGoogle Scholar
  27. 27.
    Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8:304–310CrossRefPubMedGoogle Scholar
  28. 28.
    Shuch B, Lam JS, Belldegrun AS (2006) Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 7:31–38CrossRefPubMedGoogle Scholar
  29. 29.
    Catalano C, Fraioli F, Laghi A, Napoli A, Pediconi F, Danti M, Nardis P, Passariello R (2003) High-resolution multidetector CT in the preoperative evaluation of patients with renal cell carcinoma. AJR Am J Roentgenol 180:1271–1277PubMedGoogle Scholar
  30. 30.
    Roy C Sr, El Ghali S, Buy X, Lindner V, Lang H, Saussine C, Jacqmin D (2005) Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study. AJR Am J Roentgenol 184:113–120PubMedGoogle Scholar
  31. 31.
    Kamel IR, Hochman MG, Keogan MT, Eng J, Longmaid HE 3rd, DeWolf W, Edelman RR (2004) Accuracy of breath-hold magnetic resonance imaging in preoperative staging of organ confined renal cell carcinoma. J Comput Assist Tomogr 28:327–332CrossRefPubMedGoogle Scholar
  32. 32.
    Türkvatan A, Akdur PO, Altınel M, Ölçer T, Turhan N, Cumhur T, Akıncı S, Özkul F (2009) Preoperative staging of renal cell carcinoma with multidetector CT. Diagn Interv Radiol 15:22–30PubMedGoogle Scholar
  33. 33.
    Yoo C, Song C, Hong JH, Kim CS, Ahn H (2008) Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol 180:486–491CrossRefPubMedGoogle Scholar
  34. 34.
    Hallscheidt PJ, Fink C, Haferkamp A, Bock M, Luburic A, Zuna I, Noeldge G, Kauffmann G (2005) Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr 29:64–68CrossRefPubMedGoogle Scholar
  35. 35.
    Lawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM (2005) Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int 96:291–295CrossRefPubMedGoogle Scholar
  36. 36.
    Gupta NP, Ansari MS, Khaitan A, Sivaramakrishna MS, Hemal AK, Dogra PN, Seth A (2004) Impact of imaging and thrombus level in management of renal cell carcinoma extending to veins. Urol Int 72:129–134CrossRefPubMedGoogle Scholar
  37. 37.
    Kapoor A, Nguan C, Al-Shaiji TF, Hussain A, Fazio L, Al Omar M, Luke PP (2006) Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. Urology 68:514–517CrossRefPubMedGoogle Scholar
  38. 38.
    Ciancio G, Soloway MS (2005) Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass. Urology 66:266–270CrossRefPubMedGoogle Scholar
  39. 39.
    Zini L, Haulon S, Decoene C, Amara N, Villers A, Biserte J, Leroy X, Koussa M (2005) Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies. Ann Vasc Surg 19:522–528CrossRefPubMedGoogle Scholar
  40. 40.
    Kaplan S, Ekici S, Dogan R, Demircin M, Ozen H, Pasaoglu I (2002) Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Am J Surg 183:292–299CrossRefPubMedGoogle Scholar
  41. 41.
    Jibiki M, Iwai T, Inoue Y, Sugano N, Kihara K, Hyochi N, Sunamori M (2004) Surgical strategy for treating renal cell carcinoma with thrombus extending into the inferior vena cava. J Vasc Surg 39:829–835CrossRefPubMedGoogle Scholar
  42. 42.
    Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 144:238–242PubMedGoogle Scholar
  43. 43.
    Frank I, Blute ML, Cheville JC, Lohse CM, Zincke H (2005) Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173:1889–1892CrossRefPubMedGoogle Scholar
  44. 44.
    Al Otaibi M, Abou Youssif T, Alkhaldi A, Sircar K, Kassouf W, Aprikian A, Mulder D, Tanguay S (2009) Renal cell carcinoma with inferior vena caval extention: impact of tumour extent on surgical outcome. BJU Int 104:1467–1470CrossRefPubMedGoogle Scholar
  45. 45.
    Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS (2004) Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 171:588–591CrossRefPubMedGoogle Scholar
  46. 46.
    Moinzadeh A, Libertino JA (2004) Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 171:598–601CrossRefPubMedGoogle Scholar
  47. 47.
    Karellas ME, Jang TL, Kagiwada MA, Kinnaman MD, Jarnagin WR, Russo P (2009) Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU Int 103:160–164CrossRefPubMedGoogle Scholar
  48. 48.
    Heidenreich A, Ravery V (2004) Preoperative imaging in renal cell cancer. World J Urol 22:307–315CrossRefPubMedGoogle Scholar
  49. 49.
    Ergen FB, Hussain HK, Caoili EM, Korobkin M, Carlos RC, Weadock WJ, Johnson TD, Shah R, Hayasaka S, Francis IR (2004) MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: comparison with surgical and pathologic staging. AJR Am J Roentgenol 182:217–225PubMedGoogle Scholar
  50. 50.
    Polcari AJ, Gorbonos A, Milner JE, Flanigan RC (2009) The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 16:227–233CrossRefPubMedGoogle Scholar
  51. 51.
    Rohde V (2006) Nierenzellkarinom. In: Schmelz HU, Sparwasser C, Weidner W (eds) Facharztwissen Urologie. Springer Medizin Verlag, Heidelberg, pp 146–158Google Scholar
  52. 52.
    Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC (2002) Comparing whole-body 18F–2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 128:503–506CrossRefPubMedGoogle Scholar
  53. 53.
    Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27:533–539CrossRefPubMedGoogle Scholar
  54. 54.
    Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181:518–523CrossRefPubMedGoogle Scholar
  55. 55.
    Maksimovic O, Schraml C, Hartmann JT, Bitzer M, Claussen CD, Pintoffl J, Horger M (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. Pictorial assay. AJR Am J Roentgenol 194:5–14CrossRefPubMedGoogle Scholar
  56. 56.
    Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194:157–165CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ullrich G. Mueller-Lisse
    • 1
  • Ulrike L. Mueller-Lisse
    • 2
  1. 1.Department of Radiology, Institut fuer Klinische RadiologieKlinikum der Universitaet MuenchenMunichGermany
  2. 2.Department of UrologyKlinikum der Universitaet MuenchenMunichGermany

Personalised recommendations